Dutch Court Nixes GSK Asthma Drug Patent

Law360, New York (January 27, 2011, 5:44 PM EST) -- A Dutch court has nixed GlaxoSmithKline PLC's extended patent protection for Seretide, siding with two Novartis AG generics units in a case over the blockbuster asthma treatment.

The District Court in the Hague ruled that the Dutch patent for the asthma treatment, marketed as Advair in the U.S., was no longer valid, GSK said Wednesday. The original patent had expired in September, but the company received a supplementary protection certificate in the Netherlands that granted it another three years of patent protection for the drug....
To view the full article, register now.